Understanding how certain proteins help bacteria survive in the human body.
Official title: Nitrosative stress and NO detoxifying reaction mechanisms in microbial nonheme diiron proteins
Funded at Oregon Health & Science University · NIH-11030269 · Data updated 2026-11-12
This study is looking at how certain proteins in harmful bacteria help them survive when our immune system tries to fight them off, which could lead to new ways to tackle infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | April 1, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $291,060 |
| NIH project number | 5R01GM147588-03 |
| Project ID | NIH-11030269 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with infections caused by mycobacterial pathogens, such as those with disseminated tuberculosis.
✕Less likely to help
Patients with non-infectious conditions or those not affected by mycobacterial infections may not benefit from this research.
What this research studies
This research investigates the role of metalloenzymes, specifically nonheme diiron proteins, in helping pathogenic bacteria survive the human immune response. By using advanced biochemical techniques and spectroscopies, the study aims to uncover how these proteins detoxify reactive nitrogen species, which are harmful to both bacteria and human cells. The research focuses on a unique mycobacterial protein that shows unusual structural features and reactivity, potentially revealing new insights into bacterial survival mechanisms during infections.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for combating bacterial infections by targeting their detoxification mechanisms.
How similar studies have gone: While the specific approach of investigating this novel mycobacterial protein is relatively new, similar studies on metalloenzymes have shown promise in understanding bacterial resistance mechanisms.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Moenne-Loccoz, Pierre — Oregon Health & Science University
- Study coordinator: Moenne-Loccoz, Pierre
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Understanding how AML cells become resistant to therapy over time
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.